XIAPEX Authorized in the European Union For Dupuytren's Contracture; Pfizer, Auxilium Have Marketing Rights
XIAPEX, a new non-surgical treatment option for Dupuytren's contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and is expected to be available for use in some European markets later this year.1
Collagenase clostridium histolyticum is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture. Pfizer (NYSE: PFE) has the marketing rights to collagenase clostridium histolyticum in Europe, and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) has the rights in the rest of the world.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.